Targets › DTYMK
1 program from 1 company in 1 trial: 1 Phase 2; Neurology; next expected readout Jun 2029.
Catalyzes the phosphorylation of thymidine monophosphate (dTMP) to thymidine diphosphate (dTDP), the immediate precursor for the DNA building block dTTP, with ATP as the preferred phosphoryl donor in the presence of Mg(2+). (UniProt, P23919)
Open in Phaseline: the race on DTYMK, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Kenneth Myers, MD | deoxycytidine and deoxythymidine (dC/dT) Nucleotide replacement therapy; supplies deoxycytidine and deoxythymidine to restore mitoc | TK2, DTYMK | Phase 2 | Mitochondrial Diseases | Jun 2029 |
Mitochondrial Diseases (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.